Author Guidelines


DOWNLOADABLE EDUCATION FILES

a. How to review manuscripts

b. How to write a point-by-point reply

c. How to write a cover letter

d. How to write an abstract

e. How to present data efficiently

f. How to prepare Graphical Abstracts 


Sections


1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
4. Preparing the Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication
9. Editorial Office Contact Details


1. SUBMISSION


Authors should kindly note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.


Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at https://mc.manuscriptcentral.com/allergy


Click here for more details on how to use ScholarOne.


Data protection

By submitting a manuscript to or reviewing for this publication, your name, email address, and affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.


Preprint policy

This journal will consider for review articles previously available as preprints on non-commercial servers such as ArXiv, bioRxiv, psyArXiv, SocArXiv, engrXiv, medRxiv etc. Authors may also post the submitted version of a manuscript to non-commercial servers at any time. Authors are requested to update any pre-publication versions with a link to the final published article.


For help with submissions, please contact the Editorial Office: allergy@wiley.com 


2. AIMS AND SCOPE


The aim of Allergy is to advance, impact and communicate all aspects of the discipline of Allergy/Immunology including educational, basic, translational and clinical research and maintain contact between basic and clinical Allergy/Immunology.

Allergy is an international journal with contributors and readers from all countries. Allergy publishes original articles, reviews, position papers, guidelines, editorials, news and commentaries, letters to the editors and correspondences. Articles are accepted purely on the basis of scientific merit and quality.


3. MANUSCRIPT CATEGORIES AND REQUIREMENTS


i. Editorials

Editorials are commissioned by the Editorial board. Submissions can be considered after consultation with the Editors-in-Chief only.

Title: Should be informative that establishes a link to the article that the Editorial is written for.

Text: Should be strictly limited to 1,000 words. There will not be any abstracts. References: Maximum 9 references are allowed.

Figures and tables: Maximum two display items, figures and/or tables. Figure legends should be concise and should not be more than 100 words.


ii. Position papers

Position papers are written by authors selected by the EAACI Executive Committee.

Title: Should be informative with less than 120 characters.

Short title: Should be less than 50 characters.

Keywords: up to 5, listed in alphabetical order.

Abstract: 200 words of unstructured summary.  

Text is limited to:

  • less than 4,500 words not including abstracts, figure legends and references (please supply a word count). Additional unlimited online supporting information can be provided.
  • up to 100 references in the Journal's style (if more, justification should be provided).
  • figures and tables are important in position papers and up to 10 figures and/or tables (total) can be included in the text.


iii. Review articles

Reviews should present an update of the most recent developments in a particular field of clinical allergy and immunologic research. We encourage the submission of high quality color pictures and cartoons, which may be selected for the cover of the issue.

Title: should be informative with less than 120 characters.

Short title: Should be less than 50 characters.

Keywords: up to 5, listed in alphabetical order.

Abstract: 200 words of unstructured summary.

Text:

  • less than 4,500 words not including abstract, figure legends and references (please supply a word count). Additional unlimited online supporting information can be provided.
  • up to 200 references in the Journal's style.
  • figures and tables are important in review papers and up to 10 figures and/or tables (total) can be included in the text.


iv. Original articles

We welcome high quality original publications dealing with innovative aspects of basic and clinical allergy and immunology research.

Title:

  • should be informative (example: Prevention of allergy by virus-like nanoparticles delivering shielded versions of major allergens in a humanized murine allergy model) but not descriptive (ex: Use of virus-like nanoparticles in allergy vaccines).
  • length less than 100 characters.
  • If experiments have been performed in animal models, the species should be specified in the title. 

Short title: Should be less than 50 characters

Abstract: 250 words structured as follows:

  • background (including the aims of the study).
  • methods. For animal models, specify the species.
  • results. If space is short, report only the primary outcomes.
  • conclusions.

Keywords: up to 5, listed in alphabetical order.

Text: The text is limited to:

  • less than 3,500 words not including abstract, figure legends and references (please supply a word count). Informative subtitles should be used in subsections of the results section.
  • up to 6 figures and/or tables (total) If longer, reasons for increase in length, figure or table number or reference number should be stated in the cover letter. Additional unlimited online supporting information can be provided. 

Note: Original articles are limited to 5 printed pages in total. Authors must pay GBP 80 for each additional page.

Figures: up to six figures each with many panels can be included in the original text.


v. Letters to the Editor

Letters to the Editor are brief reports that can be preliminary, but may represent original observations that may have a substantial impact within the scope of “Allergy”. They will be subject to peer review and will be indexed in Medline. They should begin with the salutation “To the Editor”. There should not be any separate abstract, but rather a conclusion paragraph sums up the Letter. Author names, affiliations, funding sources and conflict of interests should be listed at the end following references. Please note that single case reports will not be considered for publication.

Title: The title should be concise and informative. It should be less than 100 characters.

Text:

  • The text is strictly limited to maximum 1000 words. 
  • Maximum 9 references are allowed of the Journal's style. 
  • Online supplementary can be used for more references, detailed explanations of methods, sequencing databases, tables and figures. 

Figures:

  • Up to 2 display items figures and/or tables are allowed.
  • Figure legends should be concise and should not be more than 100 words.


vi. News and Views

Short manuscripts of various topics of interest to the Allergy reader. This section features research and bibliographical summaries of respected allergist/immunologists, recent patents and innovations, and clinical diagnosis and treatment algorithms. Manuscripts for this section are written by invitation only and you may include one or two co-authors to contribute to your article. 


Legends of Allergy/Immunology 

This section features eminent scientists from our specialty who have made key discoveries that have substantially changed our understanding and practice of our specialty. Legends of Allergy/Immunology are written upon invitation and the authors should get approval of the featured scientist prior to submission.

Title: “Legends of Allergy/Immunology: First and Last Name of the eminent scientist featured in the article”.

Text:

  • Maximum 5 references are allowed to be selected from the most important publications of the Scientist of interest.
  • A text box with up to six bullet points listing the year of the major discoveries/contributions of the featured scientist. 
  • The text is strictly limited to maximum 1,000 words (including the text box).

 Figures/Tables:

  • Up to 2 display items (figures and/or tables) that summarize the major contributions.
  • One of the figures should contain a high-resolution portrait photo of the featured scientist. Figure legends should be concise and not exceed 100 words.


Recent Patents in Allergy/Immunology

This new series showcases recent important patents in the allergy/immunology specialty. These “Recent Patents” articles should summarize the invention and describe its novelty and future impact. Manuscripts for this section are written upon invitation.

Title: “Recent Patents in Allergy/Immunology: Short Description of Invention”. The title should not exceed 100 characters. 

Text:

  • The text is strictly limited to maximum 1,000 words.
  • The patent registration number, application number & priority date must be provided, along with inventors (persons) and applicants (e.g., companies, universities) named in the patent.
  • Maximum 9 references are allowed.
  • The first paragraph of the text should describe the invention and its potential applications and the second paragraph should discuss the path that took you and your team to the invention, including any anecdotes that played a role in the discovery. The text should not contain an abstract but rather a conclusion paragraph that summarises the invention and its importance. 

Figures:

  • Up to 2 display items figures and/or tables are allowed.
  • Figure legends should be concise and not be more than 100 words.
  • Online supplementary space is available for additional references, tables and figures.


Medical Algorithms in Allergy/Immunology 

This new series presents summaries of diagnosis and treatment algorithms on how to approach a patient. These articles are written upon invitation of authors who have recently contributed a guideline or a position paper in the area.

Title: “Medical Algorithms: Diagnosis and Treatment of Disease”. The title should not exceed 100 characters. 

Text:

  • The text is strictly limited to maximum 600 words.
  • Maximum 9 references are allowed.

Figures:

  • Maximum two display items: a medical algorithm tree and an additional figure or table to support the medical diagnostic and treatment approach to the patient.
  • Figure legends should be detailed and can be as long as 300 words.
  • Online supplementary space is available for additional references, tables and figures. 


vii. Correspondences

Correspondences that refer to a previously published original article are welcome to be published in Allergy. 

  • The text of a correspondence is strictly limited to less than 600 words (please supply a word count).
  • Up to 6 references and one of the references must be to the article discussed.
  • One figure and/or table.

Procedure: The correspondence will be sent to the author of the article, who will have 4 weeks to answer. The correspondence and the authors’ response will be published in the same issue.


Special considerations for manuscripts dealing with particular fields


Epidemiological Studies: For reports of epidemiological studies, authors should consult the STROBE initiative.


Clinical Trials: Authors of trials should adhere to the CONSORT reporting guidelines appropriate to their trial design.


Genetic, genomic and proteomic studies: Authors of genetic association studies are strongly encouraged to consult the recommendations issued by the STREGA initiative. Database of next generation sequencing and microarray experiments should conform to the MIAME guidelines, should be available in an appropriate publicly accessible database.


Manuscripts dealing with recombinant allergens will only be considered for external review if they:

  • describe a new allergen or a class of new allergenic molecules; ii) show the clinical relevance of the allergens;
  • describe new technological approaches for cloning, production and/or characterization of allergens;
  • the sequence has been submitted, accepted and assigned with an official name by the I.U.I.S. Allergen Nomenclature Sub-committee;
  • provides a relevant progress with respect to the state of the art of the research in the field of molecular allergy;
  • manuscripts, which do not fulfil the requirements, but which contain interesting information of potential interest for the readers of Allergy, might be considered for publication as a short communication


4. PREPARING THE SUBMISSION


Cover Letters

We strongly recommend that each manuscript is accompanied by a cover letter, in which authors clearly describe why their work is novel and important and why it should be published in Allergy. This should be uploaded as the first manuscript file in your submission, designated as ‘Cover Letter’. Please download the Cover Letter Template here.


Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.


Main Text File

The text file should be presented in the following order:

i. A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
ii. A short running title of less than 50 characters;
iii. The full names of the authors;
iv. The author's institutional affiliations where the work was conducted, with a footnote for the author’s present address if different from where the work was conducted;
v. Acknowledgments;
vi. Abstract and keywords;
vii. Main text;
viii. References;
ix. Tables (each table complete with title and footnotes);
x. Figure legends;
xi. Appendices (if relevant).

Figures and supporting information should be supplied as separate files.


Authorship

Please refer to the journal’s authorship policy the Editorial Policies and Ethical Considerations section for details on eligibility for author listing.


Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.


Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the section ‘Conflict of Interest’ in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.


Graphical Abstract

The Graphical Abstract (GA) consists of:

  • GA – image, at least 300 dpi, 9:6 landscape orientation
    The image should be eye-catching and summarise the study’s major findings and should not be a duplicate of another figure in the manuscript. Any text incorporated in the image should be kept to a minimum.

Click here to download the GA template and here to download the Allergy Graphics Collection. You may copy and paste the relevant shapes into your GA.

  • Highlights
    A Word document with the title of the manuscript and three bullet points describing the graphical abstract and summarising the study’s major findings (max. of 60 words). Abbreviations included in the GA image should be spelled out and listed in alphabetical order underneath the highlights.

Files should be named as followed:

  • GA_ last name of the 1st author _ALL-xxxx_xxxxxx (saved as JPG, PNG, TIFF, PDF)
  • Highlights_ last name of the 1st author_ALL-xxxx_xxxxxx (saved as doc or docx)

and submitted in the manuscript submission system by selecting either “Graphical Abstract"
or “Graphical Abstract Highlights" from the file designation list on:
https://mc.manuscriptcentral.com/allergy


Authors are asked to consult the detailed Allergy Guidelines for Graphical Abstracts and Highlights for examples of good GAs.


Keywords

Please provide up to five keywords.


References

All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order using Arabic superscript numerals. For more information about AMA reference style please consult the AMA Manual of Style

Sample references follow:

Journal article
1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.

Book
2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Internet document
3. American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf Accessed March 3, 2003


Tables

Tables should be self-contained and complement, should not duplicate the information contained in the text. They should be supplied as editable files at the end of the manuscript text before references.The should not be copy pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.


Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.


Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.

Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

We would like that you use the figures for cell and tissue shapes that we have developed for Allergy. Click here to download the Power Point file. You can then copy and paste the relevant shapes to your Graphical Abstract.

Figures submitted in colour will be reproduced free of charge.


Data Citation

In recognition of the significance of data as an output of research effort, Wiley has endorsed the FORCE11 Data Citation Principles and is implementing a mandatory data citation policy. Wiley journals require data to be cited in the same way as article, book, and web citations and authors are required to include data citations as part of their reference list.   Data citation is appropriate for data held within institutional, subject focused, or more general data repositories. It is not intended to take the place of community standards such as in-line citation of GenBank accession codes.  When citing or making claims based on data, authors must refer to the data at the relevant place in the manuscript text and in addition provide a formal citation in the reference list. We recommend the format proposed by the Joint Declaration of Data Citation Principles:

[dataset] Authors; Year; Dataset title; Data repository or archive; Version (if any); Persistent identifier (e.g. DOI) 


Additional Files

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.


Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.


General Style Points

The following points provide general advice on formatting and style.

  • Abbreviations: Only abbreviations and symbols that are generally accepted should be used. Uncommon abbreviations must be defined when first used.


Manuscript Revision

Revised manuscripts must include the following items:

  • Responses to Comments that includes numbered point-by-point responses (you can download an example of a point by point reply) to the comments made by the Reviewers, Editor, and Editorial Office labeled as 'COMMENT' and 'RESPONSE' for each item.
  • Marked Manuscript. Any text that was not part of the original manuscript but has now been added, underline formatting should be applied; to any text that was part of the original manuscript but has now been deleted, strikethrough formatting should be applied. Changes made on Figures and Tables should be clearly visible and provided as separate files labeled as 'Figure x Marked' and 'Table x Marked'. Line numbering should be used in the Marked Manuscript and numbers mentioned in the point-by-point response to the comments.
  • Unmarked Manuscript. The Unmarked Manuscript should be your revised manuscript just as you intend it for publication (if it is accepted). Any table and figure that is to be part of your revised manuscript should be provided as a separate file (e.g., 'Figure x-Unmarked' or 'Table x- Unmarked'). Line numbering need not be used in the Unmarked Manuscript too.


Wiley Author Resources


Manuscript Preparation Tips: Wiley has a range of resources for authors preparing manuscripts for submission available here. In particular, authors may benefit from referring to Wiley’s best practice tips on Writing for Search Engine Optimization.


Editing, Translation, and Formatting Support: Wiley Editing Services can greatly improve the chances of a manuscript being accepted. Offering expert help in English language editing, translation, manuscript formatting, and figure preparation, Wiley Editing Services ensures that the manuscript is ready for submission.

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS


Peer Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. Manuscripts are single-blind peer reviewed. Papers will only be sent to review if the Editor-in-Chief determines that the paper meets the appropriate quality and relevance requirements. 

Wiley's policy on the confidentiality of the review process is available here.


Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.

Patient anonymity should be preserved. When detailed descriptions, photographs, or videos of faces or identifiable body parts are used that may allow identification, authors should obtain the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained.  Wiley has a standard patient consent form available for use. Where photographs are used they need to be cropped sufficiently to prevent human subjects being recognized; black eye bars should not be used as they do not sufficiently protect an individual’s identity).


Animal Studies

A statement indicating that the protocol and procedures employed were ethically reviewed and approved, as well as the name of the body giving approval, must be included in the Methods section of the manuscript. Authors are encouraged to adhere to animal research reporting standards, for example the ARRIVE guidelines for reporting study design and statistical analysis; experimental procedures; experimental animals and housing and husbandry. Authors should also state whether experiments were performed in accordance with relevant institutional and national guidelines for the care and use of laboratory animals:

• US authors should cite compliance with the US National Research Council's Guide for the Care and Use of Laboratory Animals, the US Public Health Service's Policy on Humane Care and Use of Laboratory Animals, and Guide for the Care and Use of Laboratory Animals.
• UK authors should conform to UK legislation under the Animals (Scientific Procedures) Act 1986 Amendment Regulations (SI 2012/3039).
• European authors outside the UK should conform to Directive 2010/63/EU.


Clinical Trial Registration

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.


Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are encouraged to adhere to recognised research reporting standards. The EQUATOR Network collects more than 370 reporting guidelines for many study types, including for:

• Randomised trials : CONSORT
• Observational studies : STROBE
• Systematic reviews : PRISMA
• Case reports : CARE
• Qualitative research : SRQR
• Diagnostic / prognostic studies : STARD
• Quality improvement studies : SQUIRE
• Economic evaluations : CHEERS
• Animal pre-clinical studies : ARRIVE
• Study protocols : SPIRIT
• Clinical practice guidelines : AGREE

We also encourage authors to refer to and follow guidelines from:

• Future of Research Communications and e-Scholarship (FORCE11)
• National Research Council's Institute for Laboratory Animal Research guidelines
• The Gold Standard Publication Checklist from Hooijmans and colleagues
• Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website
• FAIRsharing website

Please see section 3. Manuscript Categories and Requirements for specific requirements related to Original Article and Brief Communications manuscripts dealing with particular fields.


Species Names

Upon its first use in the title, abstract, and text, the common name of a species should be followed by the scientific name (genus, species, and authority) in parentheses. For well-known species, however, scientific names may be omitted from article titles. If no common name exists in English, only the scientific name should be used.


Allergen Nomenclature

The systematic allergen nomenclature of the World Health Organization/International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Sub-Committee should be used for manuscripts that include the description or use of allergenic proteins. For manuscripts describing new allergen(s), the systematic name of the allergen must be approved by the WHO/IUIS Allergen Nomenclature Sub-committee prior to manuscript publication. To avoid the risk of delay of publication, authors are encouraged to apply for a new allergen name using the posted submission form at the WHO/IUIS Allergen Nomenclature website (www.allergen.org) before manuscript submission.


Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see varnomen.hgvs.org, where examples of acceptable nomenclature are provided.


Sequence Data


Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:


Proteins sequence data should be submitted to either of the following repositories:


Structural Data

For papers describing structural data, atomic coordinates and the associated experimental data should be deposited in the appropriate databank (see below). Please note that the data in databanks must be released, at the latest, upon publication of the article. We trust in the cooperation of our authors to ensure that atomic coordinates and experimental data are released on time.

  • Organic and organometallic compounds: Crystallographic data should not be sent as Supporting Information, but should be deposited with the Cambridge Crystallographic Data Centre (CCDC) at ccdc.cam.ac.uk/services/structure%5Fdeposit.
  • Inorganic compounds: Fachinformationszentrum Karlsruhe (FIZ; fiz-karlsruhe.de).
  • Proteins and nucleic acids: Protein Data Bank (rcsb.org/pdb).
  • NMR spectroscopy data: BioMagResBank (bmrb.wisc.edu).


Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships.

Author's conflict of interest (or information specifying the absence of conflicts of interest) will be published under a separate heading entitled ‘Conflict of Interest Statement’. See here for ICMJE Form for Disclosure of Potential Conflicts of Interest.


Funding

Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/


Authorship

The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; and
2. Been involved in drafting the manuscript or revising it critically for important intellectual content; and
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

Additional Authorship Options. Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’


Data Sharing and Data Accessibility

The journal encourages authors to share the data and other artefacts supporting the results in the paper by archiving it in an appropriate public repository. Authors should include a data accessibility statement, including a link to the repository they have used, in order that this statement can be published alongside their paper.


Human subject information in databases. The journal refers to the World Health Medical Association Declaration of Taipei on Ethical Considerations Regarding Health Databases and Biobanks.


ORCID

As part of the journal’s commitment to supporting authors at every step of the publishing process, the journal requires the submitting author (only) to provide an ORCID iD when submitting a manuscript. This takes around 2 minutes to complete. Find more information here.


Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.


Supplements

These are papers exceeding 20 printed pages whose publication is paid for entirely by the author. Although supplements must be accepted by the editorial office, the journal does not hold itself responsible for all statements made by contributors. After acceptance, supplements do not undergo editorial revision, but should be as similar as possible in style (especially citation style) and format to original articles. It is Wiley´s policy to acknowledge in supplements any major sponsorship. Supplements are not peer reviewed.


6. AUTHOR LICENSING


If your paper is accepted, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they will be required to complete a copyright license agreement on behalf of all authors of the paper.

Authors may choose to publish under the terms of the journal’s standard copyright agreement, or OnlineOpen under the terms of a Creative Commons License.

General information regarding licensing and copyright is available here. To review the Creative Commons License options offered under OnlineOpen, please click here. (Note that certain funders mandate that a particular type of CC license has to be used; to check this please click here.)

Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.

Open Access fees: If you choose to publish using OnlineOpen you will be charged a fee. A list of Article Publication Charges for Wiley journals is available here.

Funder Open Access: Please click here for more information on Wiley’s compliance with specific Funder Open Access Policies.


7. PUBLICATION PROCESS AFTER ACCEPTANCE


Accepted article received in production

When an accepted article is received by Wiley’s production team, the corresponding author will receive an email asking them to login or register with Wiley Author Services. The author will be asked to sign a publication license at this point.


Accepted Articles

The journal offers Wiley’s Accepted Articles service for all manuscripts. This service ensures that accepted ‘in press’ manuscripts are published online shortly after acceptance, prior to copy-editing or typesetting. Accepted Articles are published online a few days after final acceptance and appear in PDF format only. They are given a Digital Object Identifier (DOI), which allows them to be cited and tracked and are indexed by PubMed. After the final version article is published (the article of record), the DOI remains valid and can still be used to cite and access the article.

Accepted Articles will be indexed by PubMed; submitting authors should therefore carefully check the names and affiliations of all authors provided in the cover page of the manuscript so it is accurate for indexing. Subsequently, the final copyedited and proofed articles will appear in an issue on Wiley Online Library; the link to the article in PubMed will update automatically.


Proofs

Once the paper is typeset, the author will receive an email notification with the URL to download a PDF typeset page proof, as well as associated forms and full instructions on how to correct and return the file.

Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt of first proof.


Publication Charges


Page Charges. Original Articles are limited to 5 printed pages in total. Authors must pay GBP 80 for each additional page. The author will be notified of the cost of page charges when they receive the proofs, along with instructions on how to pay for the charges.


Early View

The journal offers rapid speed to publication via Wiley’s Early View service. Early View (Online Version of Record) articles are published on Wiley Online Library before inclusion in an issue. Note there may be a delay after corrections are received before the article appears online, as Editors also need to review proofs. Once the article is published on Early View, no further changes to the article are possible. The Early View article is fully citable and carries an online publication date and DOI for citations.


8. POST PUBLICATION


Access and sharing

When the article is published online:

• The author receives an email alert (if requested).
• The link to the published article can be shared through social media.
• The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
• The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.


Promoting the Article

To find out how to best promote an article, click here.


Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.


9. EDITORIAL OFFICE CONTACT DETAILS


For queries about submissions, please contact allergy@wiley.com


Author Guidelines Updated 18 October 2019